A Randomized, Placebo-Controlled, Phase 2 Study of the Safety, Pharmacokinetics and Pharmacodynamics of CVT-310 (Levodopa Inhalation Powder) in Patients With Parkinson's Disease and Motor Response Fluctuations ("Off Episodes")
Latest Information Update: 02 Nov 2021
Price :
$35 *
At a glance
- Drugs Levodopa (Primary) ; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Acorda Therapeutics; Civitas Therapeutics
- 22 Sep 2021 Results of meta-analysis of 3 studies (phase 3, double-blind study of CVT-301 in patients with PD were combined with results from a 4-week, phase 2b, double-blind, placebo-controlled study and a 12-month safety study compared to an observational cohort (OC) control) assessing safety were presented at the 25th International Congress of Parkinson's Disease and Movement Disorders.
- 13 Oct 2016 Results from this and phase I trials of CVT-301 published in the Scince Tanslation Medicine, according to an Acorda Therapeutics.
- 03 May 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.